Belite Bio’s lead candidate, LBS−008, is an oral therapy designed to reduce the accumulation of toxic vitamin A metabolites (A2E)

Belite Bio’s lead candidate, LBS−008, is an oral therapy designed to reduce the accumulation of toxic vitamin A metabolites (A2E) in the retina. These metabolites are implicated in the progression of Stargardt disease and dry AMD, leading to vision loss. By inhibiting the formation of A2E, LBS−008 aims to preserve retinal health and slow disease progression. Belite Bio is also developing therapies for NASH, a serious liver disease characterized by fat accumulation, inflammation, and fibrosis. The company’s approach involves targeting key pathways involved in the disease process to reduce liver fat, inflammation, and fibrosis, potentially reversing disease progression.